CNBC
Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
Wednesday, November 18, 2026
Hims & Hers began offering compounded forms of sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine through its telehealth platform. None of these compounds are approved by the FDA for the marketed purposes. The company acknowledged in its announcement that additional research is needed to establish efficacy.
Original reporting:
